Skip to main content

Table 1 Baseline characteristics of ADPKD patients

From: Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease

 

Standard care

Tolvaptan

Lanreotide

N

127

27

25

Age (yrs)

40.9 ± 11.0

46.3 ± 9.8

47.4 ± 9.7

Female, n (%)

56 (44.1)

12 (48.1)

11 (44.0)

BMI (kg/m2)

26.0 ± 4.6

25.7 ± 4.1

27.7 ± 5.4

BSA (m2)

2.03 ± 0.25

2.02 ± 0.28

2.04 ± 0.25

SBP (mm Hg)

128 ± 12.2

131 ± 10.7

140 ± 10.6

DBP (mm Hg)

78.7 ± 9.23

81.3 ± 7.6

88.1 ± 8.3

AHT n, (%)

99 (78.0)

24 (88.9)

22 (88.0)

Sodium intake (mmol/24 h)

170 ± 68.9

202 ± 92.7

168 ± 59.0

Protein intake (g/24 h)

85.7 ± 21.0

110 ± 38.5

67.8 ± 16.7

Coffee use (cups/day)

3 (1–5)

NA

NA

eGFR (ml/min/1.73m2)

72.5 ± 31.6

57.0 ± 33.1

51.0 ± 11.6

mGFR (ml/min/1.73m2)

75.2 ± 32.0

60.8 ± 34.7

NA

htTKV (mL/m)

826 (521–1297)

1242 (608–1505)

1150 (650–1833)

PKD mutation, n (%)

 PKD1 truncating

48 (37.8)

3 (11.1)

9 (36.0)

 PKD1 non-truncating

30 (23.6)

5 (18.5)

8 (32.0)

 PKD2

13 (10.2)

4 (14.8)

4 (16.0)

 No mutation detected

2 (1.6)

0 (0.0)

0 (0.0)

 Missing

34 (26.8)

15 (55.6)

4 (16.0)

Somatostatin (pg/mL)

48.5 (34.3–77.8)

38.2 (23.8–70.6)

42.5 (33.2–55.0)

  1. Variables are presented as mean ± SD when normally distributed, when non-normally distributed as median (IQR)
  2. Abbreviations are: N number, BMI body mass index, BSA body surface area, SBP systolic blood pressure, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, mGFR measured glomerular filtration rate, htTKV height adjusted total kidney volume, PKD polycystic kidney disease, NA not available
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us